Earned Wealth Advisors LLC Increases Stake in Natera, Inc. (NASDAQ:NTRA)

Earned Wealth Advisors LLC increased its position in Natera, Inc. (NASDAQ:NTRA) by 5.0% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 1,737 shares of the medical research company’s stock after acquiring an additional 82 shares during the quarter. Earned Wealth Advisors LLC’s holdings in Natera were worth $246,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Bank of Nova Scotia bought a new position in Natera in the 1st quarter worth about $370,000. Banco Santander S.A. bought a new position in Natera in the 1st quarter worth about $3,250,000. PNC Financial Services Group Inc. boosted its stake in Natera by 42.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 4,206 shares of the medical research company’s stock worth $595,000 after purchasing an additional 1,255 shares during the period. Commerce Bank boosted its stake in Natera by 7.0% in the 1st quarter. Commerce Bank now owns 2,835 shares of the medical research company’s stock worth $401,000 after purchasing an additional 185 shares during the period. Finally, Bank of Jackson Hole Trust bought a new position in Natera in the 1st quarter worth about $29,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

NTRA has been the subject of several analyst reports. Barclays raised their target price on Natera from $160.00 to $190.00 and gave the stock an “overweight” rating in a research note on Friday, May 9th. Evercore ISI upgraded Natera to a “strong-buy” rating and set a $170.00 target price for the company in a research note on Monday, July 28th. Piper Sandler raised their target price on Natera from $205.00 to $210.00 and gave the stock an “overweight” rating in a research note on Thursday, May 15th. UBS Group raised their price target on Natera from $211.00 to $218.00 and gave the company a “buy” rating in a report on Friday, May 9th. Finally, Wall Street Zen cut Natera from a “hold” rating to a “sell” rating in a report on Saturday, May 17th. One research analyst has rated the stock with a sell rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and a consensus target price of $183.76.

Insider Buying and Selling

In other news, CFO Michael Burkes Brophy sold 3,045 shares of Natera stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $137.40, for a total value of $418,383.00. Following the sale, the chief financial officer directly owned 65,430 shares in the company, valued at approximately $8,990,082. This trade represents a 4.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gail Boxer Marcus sold 4,299 shares of Natera stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $167.36, for a total value of $719,480.64. Following the completion of the sale, the director owned 8,118 shares in the company, valued at approximately $1,358,628.48. This represents a 34.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 48,936 shares of company stock valued at $7,483,846 in the last 90 days. 7.60% of the stock is owned by insiders.

Natera Trading Up 1.5%

Shares of NASDAQ NTRA opened at $136.57 on Tuesday. The stock has a market cap of $18.65 billion, a price-to-earnings ratio of -92.90 and a beta of 1.76. Natera, Inc. has a 1-year low of $92.14 and a 1-year high of $183.00. The stock’s 50-day moving average is $156.83 and its 200 day moving average is $155.54.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.09. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The business had revenue of $501.83 million for the quarter, compared to analyst estimates of $446.68 million. During the same period last year, the company earned ($0.56) EPS. Natera’s revenue for the quarter was up 36.5% compared to the same quarter last year. On average, analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.